PDGFRB and chronic myelogenous leukemia, BCR-ABL1 positive: The leading drug in this area is imatinib mesylate, which targets ABL, KIT and PDGFR. It has been remarkably effective in the treatment of chronic myeloid leukaemia, although resistance remains a significant problem.